Inhibikase Therapeutics Inc. (IKT)
Market Closed
17 Jul, 20:00
NASDAQ (CM) NASDAQ (CM) Primary 
XMUN $
2. 11
+0.1
+4.9751%
$
271.99M Market Cap
- P/E Ratio
- Div Yield
1.74M Volume
-1.77 Eps
$ 2.01
Previous Close 
Want to track IKT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Inhibikase Therapeutics Inc. (IKT) Statistics
Valuation metrics
Market Cap 271.99M
Enterprise value 229.02M
Trailing P/E (ttm) -3.91
Forward P/E -
PEG ratio -0.04
Price/Sales (ttm) -
Price/Book (mrq) 1.24
Enterprise Value/Revenue -
Enterprise Value/EBITDA -4.25
Overview
Shares outstanding -
Float -
Shares short -
% Held by insiders -
% Held by institutions -
Average volume (10 days) 1.74M
Average volume (90 days) 846.6K
Price summary
52-Week low 1.33
52-Week high 2.36
Beta -
50-Day moving average 1.81
200-Day moving average 1.8
Dividends and splits
Forward annual dividend rate -
Forward annual dividend yield -
Trailing annual dividend rate -
Trailing annual dividend yield -
5-Year annual dividend yield -
Payout ratio -
Dividend Date -
Ex-Dividend Date -
Last split factor 1:6
Last split Date 30 Jun 2023
Financials
Fiscal year
Fiscal year ends -
Most recent quarter (mrq) -
Profitability
Profit margin -
Operating margin -
Operational effectiveness
Return on assets -0.29%
Return on equity -0.41%
Income Statement
Revenue (ttm) -
Revenue per share (ttm) -
Quarterly revenue growth (yoy) -
Gross profit (ttm) -
EBITDA -
Net income to common (ttm) -
Diluted EPS (ttm) -0.52
Quarterly earnings growth (yoy) -
Balance Sheet
Total cash (mrq) -
Total cash per share (mrq) 1.73
Total debt (mrq) -
Total Debt/Equity (mrq) -
Current ratio (mrq) 30.14%
Book value per share (mrq) 1.71
Cash Flow
Cash flow statement -
Levered free cash flow (LFCF) -
